# Cytokinetics Presents Positive Phase 3 Aficamten Data in Non-Obstructive HCM

- URL: https://stocks.freetheai.org/news/cytokinetics-presents-positive-phase-3-aficamten-data-in-non-obstructive-hcm-d9efa8
- Published: 2026-10-12T20:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:CYTK](https://stocks.freetheai.org/symbols/NASDAQ-CYTK)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Cytokinetics, Incorporated (NASDAQ:CYTK) presented new clinical data from its Phase 3 trial evaluating aficamten in patients with non-obstructive hypertrophic cardiomyopathy. At 36 weeks, treatment with aficamten led to statistically significant improvements in overall exercise performance and cardiac health metrics compared to placebo. Overall, 53% of patients receiving aficamten showed clinical responses across three or more key health domains, compared to 13% of patients in the placebo group.

The additional analyses offer a deeper look into how the drug affects physical capacity and heart function in non-obstructive cases of the disease. In safety monitoring, dose adjustments resulted in predictable drug concentrations and stable heart function after week eight. A lower left ventricular ejection fraction occurred in 10.5% of aficamten patients versus 0.8% on placebo, while serious heart failure events occurred in 4.7% of aficamten patients compared to 1.2% receiving placebo.

Looking ahead, the company plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration during the current quarter to seek approval for aficamten in non-obstructive hypertrophic cardiomyopathy. Shares of Cytokinetics were trading up 0.37% at $63.14 following the announcement.

## Key points

- Cytokinetics presented additional Phase 3 trial data showing aficamten significantly improved exercise performance and health status in non-obstructive HCM patients.
- Clinical responses in three or more efficacy domains were observed in 53% of aficamten patients compared with 13% on placebo.
- Serious heart failure events occurred in 4.7% of aficamten patients versus 1.2% on placebo, with all aficamten events occurring prior to Week 12.
- Cytokinetics plans to file a supplemental New Drug Application with the U.S. FDA during the fourth quarter of 2026.

## Questions and answers

### What new trial data did Cytokinetics present for aficamten?

Cytokinetics presented Phase 3 trial data showing aficamten significantly improved global exercise performance and clinical measures at 36 weeks in patients with non-obstructive hypertrophic cardiomyopathy compared to placebo.

### What is the safety profile reported for aficamten in the study?

Low ejection fraction occurred in 10.5% of aficamten patients compared to 0.8% on placebo, and serious heart failure events occurred in 4.7% versus 1.2% on placebo, with all events responding to standard medical treatment.

### What is Cytokinetics' next regulatory step for aficamten?

Cytokinetics plans to submit a supplemental New Drug Application to the U.S. FDA in the fourth quarter of 2026 for aficamten in non-obstructive hypertrophic cardiomyopathy.